Dashboard
Manage Tickers

CRVS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

casella-waste-systems-ses-ai-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Casella Waste Systems, SES AI And Other Bi...
09/18/2024 12:12:31

ladenburg-thalmann-maintains-buy-on-corvus-pharma-raises-price-target-to-21
Ladenburg Thalmann Maintains Buy on Corvus...
09/16/2024 16:37:47

Ladenburg Thalmann analyst Aydin Huseynov maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from ...

alcoa-lattice-semiconductor-stratasys-and-other-big-stocks-moving-higher-on-monday
Alcoa, Lattice Semiconductor, Stratasys An...
09/16/2024 14:03:58

corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for-patients-with-relapsedrefractory-peripheral-t-cell-lymphoma
Corvus Pharmaceuticals Initiates Registrat...
09/10/2024 12:30:37

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently...

why-fortinet-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket
Why Fortinet Shares Are Trading Higher By ...
08/07/2024 10:04:36

corvus-pharma-q2-eps-007-beats-012-estimate
Corvus Pharma Q2 EPS $(0.07) Beats $(0.12)...
08/06/2024 20:02:32

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12)...

corvus-pharmaceuticals-announces-fda-fast-track-designation-for-soquelitinib-in-treatment-of-relapsed-or-refractory-ptcl-phase-3-clinical-trial-to-begin-initial-enrollment-in-q3-2024
Corvus Pharmaceuticals Announces FDA Fast ...
08/01/2024 12:41:45

corvus-pharmaceuticals-announces-publication-in-science-signaling-demonstrating-itk-inhibition-by-soquelitinib-induces-anti-inflammatory-treg-cells-study-highlights-potential-for-treating-inflammatory-autoimmune-and-allergic-diseases
Corvus Pharmaceuticals Announces Publicati...
07/25/2024 12:35:13

oppenheimer-maintains-outperform-on-corvus-pharma-raises-price-target-to-8
Oppenheimer Maintains Outperform on Corvus...
05/07/2024 12:06:09

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 t...

corvus-pharma-expects-fy24-net-cash-used-in-operating-activities-24m-27m-resulting-in-projected-cash-balance-of-31m-34m-at-dec-31-2024-expects-cash-to-find-operations-into-q4-2025
Corvus Pharma Expects FY24 Net Cash Used I...
05/06/2024 20:03:58

corvus-pharma-q1-2024-gaap-eps-012-inline
Corvus Pharma Q1 2024 GAAP EPS $(0.12), In...
05/06/2024 20:02:03

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.

corvus-pharmaceuticals-announces-pricing-of-306m-registered-direct-offering
Corvus Pharmaceuticals Announces Pricing O...
05/02/2024 12:40:18

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical compan...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 20:31:18

corvus-pharmaceuticals-announces-initiation-of-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis
Corvus Pharmaceuticals Announces Initiatio...
04/09/2024 20:02:18

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's select...

cantor-fitzgerald-reiterates-overweight-on-corvus-pharma
Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 15:16:33

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight.

mizuho-maintains-neutral-on-corvus-pharma-maintains-35-price-target
Mizuho Maintains Neutral on Corvus Pharma,...
03/27/2024 17:21:58

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Neutral and maintains $3.5 price target.

oppenheimer-maintains-outperform-on-corvus-pharma-lowers-price-target-to-7
Oppenheimer Maintains Outperform on Corvus...
03/20/2024 11:14:14

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 t...

corvus-pharma-q4-eps-014-misses-012-estimate
Corvus Pharma Q4 EPS $(0.14) Misses $(0.12...
03/19/2024 20:04:29

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.1...

earnings-scheduled-for-march-19-2024
Earnings Scheduled For March 19, 2024
03/19/2024 10:06:23

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...

earnings-outlook-for-corvus-pharma
Earnings Outlook For Corvus Pharma
03/18/2024 14:00:39

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION